Biotech Values

[iwfal]

AMRN

Given this fact situation, sales WILL increase, likely to billions as most people on statins take Vascepa too.

While I agree sales will increase, I doubt it will get anywhere close to “most” patients taking statins. Almost certainly true statins have fewer side effects than Vascepa (albeit ones that are less noticeable to patients), plus statins are approved for the full spectrum of primary patients.

(The argument in favor of Vascepa taking large share is that ppl much prefer to take something “natural” for treatment of asymptomatic patients - but I doubt that effect is strong enough to overcome the real bleeding risks and the lack of a full primary care label)